Toxic iron species in lower-risk myelodysplastic syndrome patients : course of disease and effects on outcome

Autor: Hoeks, Marlijn, Bagguley, Tim, van Marrewijk, Corine, Smith, Alex, Bowen, David, Culligan, Dominic, Kolade, Seye, Symeonidis, Argiris, Garelius, Hege, Spanoudakis, Michail, Langemeijer, Saskia, Roelofs, Rian, Wiegerinck, Erwin, Tatic, Aurelia, Killick, Sally, Panagiotidis, Panagiotis, Stanca, Oana, Hellström-Lindberg, Eva, Cermak, Jaroslav, van der Klauw, Melanie, Wouters, Hanneke, van Kraaij, Marian, Blijlevens, Nicole, Swinkels, Dorine W., de Witte, Theo, Stauder, R., Walder, A., Pfeilstöcker, M., Schoenmetzler-Makrai, A., Burgstaller, S., Thaler, J., Mandac Rogulj, I., Krejci, M., Voglova, J., Rohon, P., Jonasova, A., Cermak, J., Mikulenkova, D., Hochova, I., Jensen, P. D., Holm, M. S., Kjeldsen, L., Dufva, I. H., Vestergaard, H., Re, D., Slama, B., Fenaux, P., Choufi, B., Cheze, S., Klepping, D., Salles, B., de Renzis, B., Willems, L., De Prost, D., Gutnecht, J., Courby, S., Siguret, V., Tertian, G., Pascal, L., Chaury, M., Wattel, E., Guerci, A., Legros, L., Itzykson, R., Ades, L., Isnard, F., Sanhes, L., Benramdane, R., Stamatoullas, A., Amé, S., Beyne-Rauzy, O., Gyan, E., Platzbecker, U., Badrakan, C., Germing, U., Lübbert, M., Schlenk, R., Kotsianidis, I., Tsatalas, C., Pappa, V., Galanopoulos, A., Michali, E., Panagiotidis, P., Viniou, N., Katsigiannis, A., Roussou, P., Terpos, E., Kostourou, A., Kartasis, Z., Pouli, A., Palla, K., Briasoulis, V., Hatzimichael, E., Vassilopoulos, G., Symeonidis, A., Kourakli, A., Zikos, P., Anagnostopoulos, A., Kotsopoulou, M., Megalakaki, K., Protopapa, M., Vlachaki, E., Konstantinidou, P., Stemer, G., Nemetz, A., Gotwin, U., Cohen, O., Koren, M., Levy, E., Greenbaum, U., Gino-Moor, S., Price, M., Ofran, Y., Winder, A., Goldshmidt, N., Elias, S., Sabag, R., Hellman, I., Ellis, M., Braester, A., Rosenbaum, H., Berdichevsky, S., Itzhaki, G., Wolaj, O., Yeganeh, S., Katz, O., Filanovsky, K., Dali, N., Mittelman, M., Malcovati, L., Fianchi, L., vd Loosdrecht, A., Matthijssen, V., Herbers, A., Pruijt, H., Aboosy, N., de Vries, F., Velders, G., Jacobs, E., Langemeijer, S., MacKenzie, M., Lensen, C., Kuijper, P., Madry, K., Camara, M., Almeida, A., Vulkan, G., Stanca Ciocan, O., Tatic, A., Savic, A., Pedro, C., Xicoy, B., Leiva, P., Munoz, J., Betes, V., Benavente, C., Lozano, M., Martinez, M., Iniesta, P., Bernal, T., Diez Campelo, M., Tormo, D., Andreu Lapiedra, R., Sanz, G., Hesse Sundin, E., Garelius, H., Karlsson, C., Antunovic, P., Jönsson, A., Brandefors, L., Nilsson, L., Kozlowski, P., Hellstrom-Lindberg, E., Grövdal, M., Larsson, K., Wallvik, J., Lorenz, F., Ejerblad, E., Culligan, D., Craddock, C., Kolade, S., Cahalin, P., Killick, S., Ackroyd, S., Wong, C., Warren, A., Drummond, M., Hall, C., Rothwell, K., Green, S., Ali, S., Bowen, D., Karakantza, M., Dennis, M., Jones, G., Parker, J., Bowen, A., Radia, R., Das-Gupta, E., Vyas, P., Nga, E., Creagh, D., Ashcroft, J., Mills, J., Bond, L.

Publikováno v: Hoeks, M, Bagguley, T, van Marrewijk, C, Smith, A, Bowen, D, Culligan, D, Kolade, S, Symeonidis, A, Garelius, H, Spanoudakis, M, Langemeijer, S, Roelofs, R, Wiegerinck, E, Tatic, A, Killick, S, Panagiotidis, P, Stanca, O, Hellström-Lindberg, E, Cermak, J, van der Klauw, M, Wouters, H, van Kraaij, M, Blijlevens, N, Swinkels, D W, de Witte, T, Stauder, R, Walder, A, Pfeilstöcker, M, Schoenmetzler-Makrai, A, Burgstaller, S, Thaler, J, Mandac Rogulj, I, Krejci, M, Voglova, J, Rohon, P, Jonasova, A, Cermak, J, Mikulenkova, D, Hochova, I, Jensen, P D, Holm, M S, Kjeldsen, L, Dufva, I H, Vestergaard, H, Re, D, Slama, B, Fenaux, P, Choufi, B, Cheze, S, Klepping, D, Salles, B, de Renzis, B, Willems, L, De Prost, D, Gutnecht, J, Courby, S, Siguret, V, Tertian, G, Pascal, L, Chaury, M, Wattel, E, Guerci, A, Legros, L, Itzykson, R, Ades, L, Isnard, F, Sanhes, L, Benramdane, R, Stamatoullas, A, Amé, S, Beyne-Rauzy, O, Gyan, E, Platzbecker, U, Badrakan, C, Germing, U, Lübbert, M, Schlenk, R, Kotsianidis, I, Tsatalas, C, Pappa, V, Galanopoulos, A, Michali, E, Panagiotidis, P, Viniou, N, Katsigiannis, A, Roussou, P, Terpos, E, Kostourou, A, Kartasis, Z, Pouli, A, Palla, K, Briasoulis, V, Hatzimichael, E, Vassilopoulos, G, Symeonidis, A, Kourakli, A, Zikos, P, Anagnostopoulos, A, Kotsopoulou, M, Megalakaki, K, Protopapa, M, Vlachaki, E, Konstantinidou, P, Stemer, G, Nemetz, A, Gotwin, U, Cohen, O, Koren, M, Levy, E, Greenbaum, U, Gino-Moor, S, Price, M, Ofran, Y, Winder, A, Goldshmidt, N, Elias, S, Sabag, R, Hellman, I, Ellis, M, Braester, A, Rosenbaum, H, Berdichevsky, S, Itzhaki, G, Wolaj, O, Yeganeh, S, Katz, O, Filanovsky, K, Dali, N, Mittelman, M, Malcovati, L, Fianchi, L, vd Loosdrecht, A, Matthijssen, V, Herbers, A, Pruijt, H, Aboosy, N, de Vries, F, Velders, G, Jacobs, E, Langemeijer, S, MacKenzie, M, Lensen, C, Kuijper, P, Madry, K, Camara, M, Almeida, A, Vulkan, G, Stanca Ciocan, O, Tatic, A, Savic, A, Pedro, C, Xicoy, B, Leiva, P, Munoz, J, Betes, V, Benavente, C, Lozano, M, Martinez, M, Iniesta, P, Bernal, T, Diez Campelo, M, Tormo, D, Andreu Lapiedra, R, Sanz, G, Hesse Sundin, E, Garelius, H, Karlsson, C, Antunovic, P, Jönsson, A, Brandefors, L, Nilsson, L, Kozlowski, P, Hellstrom-Lindberg, E, Grövdal, M, Larsson, K, Wallvik, J, Lorenz, F, Ejerblad, E, Culligan, D, Craddock, C, Kolade, S, Cahalin, P, Killick, S, Ackroyd, S, Wong, C, Warren, A, Drummond, M, Hall, C, Rothwell, K, Green, S, Ali, S, Karakantza, M, Dennis, M, Jones, G, Parker, J, Bowen, A, Radia, R, Das-Gupta, E, Vyas, P, Nga, E, Creagh, D, Ashcroft, J, Mills, J, Bond, L & the EUMDS Registry Participants 2021, ' Toxic iron species in lower-risk myelodysplastic syndrome patients : course of disease and effects on outcome ', Leukemia, vol. 35, no. 6, pp. 1745-1750 . https://doi.org/10.1038/s41375-020-01022-2
on behalf of the EUMDS Registry Participants 2021, ' Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome ', Leukemia, vol. 35, no. 6, pp. 1745-1750 . https://doi.org/10.1038/s41375-020-01022-2
Hoeks, M, Bagguley, T, van Marrewijk, C, Smith, A, Bowen, D, Culligan, D, Kolade, S, Symeonidis, A, Garelius, H, Spanoudakis, M, Langemeijer, S, Roelofs, R, Wiegerinck, E, Tatic, A, Killick, S, Panagiotidis, P, Stanca, O, Hellström-Lindberg, E, Cermak, J, van der Klauw, M, Wouters, H, van Kraaij, M, Blijlevens, N, Swinkels, D W, de Witte, T, on behalf of the EUMDS Registry Participants & Vestergaard, H 2021, ' Toxic iron species in lower-risk myelodysplastic syndrome patients : course of disease and effects on outcome ', Leukemia, vol. 35, no. 6, pp. 1745-1750 . https://doi.org/10.1038/s41375-020-01022-2
Leukemia, 35, 1745-1750
Leukemia, 35, 1745-1750. Nature Publishing Group
Leukemia, 35(6), 1745-1750. Nature Publishing Group
Leukemia, 35, 6, pp. 1745-1750
Leukemia

Red blood cell transfusions (RBCT) remain the cornerstone of supportive care in lower-risk myelodysplastic syndrome (LRMDS) [1]. Transfusion dependency in LRMDS patients is associated with inferior outcomes, mainly attributed to severe bone marrow fa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b23cc5efb8d641ceed6da88864dd77a4
https://eprints.whiterose.ac.uk/165856/1/s41375_020_01022_2.pdf

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

Autor: Saussele, S. Richter, J. Guilhot, J. Gruber, F.X. Hjorth-Hansen, H. Almeida, A. Janssen, J.J.W.M. Mayer, J. Koskenvesa, P. Panayiotidis, P. Olsson-Strömberg, U. Martinez-Lopez, J. Rousselot, P. Vestergaard, H. Ehrencrona, H. Kairisto, V. Machová Poláková, K. Müller, M.C. Mustjoki, S. Berger, M.G. Fabarius, A. Hofmann, W.-K. Hochhaus, A. Pfirrmann, M. Mahon, F.-X. Ossenkoppele, G. Pagoni, M.N. Söderlund, S. Escoffre-Barbe, M. Etienne, G. Dengler, J. Huguet, F. von Bubnoff, N. Klamova, H. Faber, E. Guilhot, F. Lotfi, K. Rea, D. Brümmendorf, T.H. de Greef, G.E. Stenke, L. Nicolini, F.E. Legros, L. Burchert, A. Voglova, J. Charbonnier, A. Gyan, E. Kunzmann, V. Westerweel, P.E. EURO-SKI investigators

Background: Tyrosine kinase inhibitors (TKIs) have improved the survival of patients with chronic myeloid leukaemia. Many patients have deep molecular responses, a prerequisite for TKI therapy discontinuation. We aimed to define precise conditions fo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::b48225bad621c9642164ddf6326658ca
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3107377

Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic

Autor: Klamova H, Faber E, Zackova D, Markova M, Voglova J, Cmunt E, Novakova L, Kateřina Machová Poláková, Moravcova J, Dvorakova D, Michalova K, Brezinova J, Oltova A, Jarosova M, Cetkovsky P, Indrak K, Mayer J

Publikováno v: Europe PubMed Central

Dasatinib is effective second line treatment for patients with chronic myeloid leukemia (CML) resistant or intolerant to imatinib. We report here the first experiences with dasatinib therapy in 71 CML patients resistant or intolerant to imatinib from

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::7bc42a9cc46acc11d4ee029c09278cfe
https://pubmed.ncbi.nlm.nih.gov/20429627

Comparative trial of BBR 2778 (pixantrone) plus rituximab vs single agent rituximab in the treatment of relapsed/refractory indolent non-Hodgkin's lymphoma (NHL)

Autor: Santoro, A, Voglova, J, Gabrail, N, Ciuleanu, T, Liberati, Anna Marina

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3982::693058ccb43996683a02c512a2f53b9e
http://hdl.handle.net/11391/1019866

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.